• Phio Pharmaceuticals Corp PHIO.OQ reported a quarterly adjusted loss of 85 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-7.65. The lone analyst forecast for the quarter was for a loss of $1.23 per share.

• Reported revenue was zero​; analysts expected zero.

• Phio Pharmaceuticals Corp's reported EPS for the quarter was a loss of 85 cents​.

• The company reported a quarterly loss of $1.63 million.

• Phio Pharmaceuticals Corp shares had held steady so far this quarter and lost 27.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 65.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Phio Pharmaceuticals Corp is $4.00

This summary was machine generated from LSEG data April 1 at 09:06 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)